Progyny, Inc. (PGNY) is a leading United States-based benefits management company, specialized in fertility and family building benefits solutions. Established in 2008 and headquartered in New York, the company aims to redefine fertility and family building benefits, providing comprehensive value-driven health coverage solutions and employee benefits.
Progyny is rooted in a clear mission: to ensure that anyone who wants to have a child can do so. To achieve this, the company uses a unique, patient-centric approach, providing innovative treatment solutions, including In Vitro Fertilization (IVF) and egg freezing. Progyny's services are designed to improve outcomes, shorten time frames, and reduce the cost of fertility care.
Progyny, Inc (PGNY) is not just any benefits management company. It focuses on delivering a unique and specialized service that significantly impacts individual lives and families. The company consistently works towards removing barriers to fertility management and care, with a commitment to helping people in their quest to start families. Their philosophy is centered around the understanding that the path to parenity is unique for everyone, providing personalized treatment plans for the people who use their service.
Recognized as the “Best Fertility Benefits Solution” during the 2019 annual Healthcare Revolution Conference, Progyny is renowned for its Smart Cycle benefit plans. The company works in collaboration with a large network of premier fertility specialists throughout the US. This means they both provide access to top-level fertility services and also cover treatment expenses, ensuring affordability of care.
With a client base that includes employers from various sectors, Progyny allows enterprises to offer fertility benefits as an integral part of their employee benefits package. By doing this, they help attract and retain staff, while simultaneously improving the overall wellbeing of the workforce.
Progyny, Inc. (PGNY) has made great strides in this relatively new market. It is now listed on the NASDAQ Stock Market and continues to grow with a strong market presence. The company also continues to invest in research and development, focusing on pushing the boundaries of fertility and family-building benefits. Their dedication to transforming the fertility sector sets Progyny apart from other benefits management companies and it shows in their innovation and leadership in this field. Their dedication to patient satisfaction and the fulfillment of family-building dreams fuels their commitment to providing unparalleled fertility benefits solutions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Progyny, Inc. director Gordon Kevin K exercised 22,000 stock options at $13 per share on September 10, 2026. On the same day, he also forfeited 10,500 shares at $27.24 each and sold 11,500 shares at $27.94 each. These transactions adjusted his direct shareholdings to 6,792 shares and derivative securities to 22,000 shares.
This article analyzes the Q2 earnings season for health insurance providers, highlighting Progyny (NASDAQ:PGNY) as having the weakest guidance update despite a revenue beat. It contrasts Progyny's performance with other companies like CVS Health, Molina Healthcare, Alignment Healthcare, and Clover Health, detailing their Q2 results. The article also touches upon broader industry challenges and tailwinds, including regulatory scrutiny, AI's impact, and changing market concerns from AI to geopolitics.
Progyny, Inc. insider Swartz Allison forfeited 1,307 shares in two separate transactions on September 3 and September 4, 2026. The shares were priced between $26.29 and $26.61, and these forfeitures were classified as tax-related withholdings. Following these transactions, Swartz Allison's remaining ownership in Progyny stands at 79,719 shares.
Progyny's CFO, Mark S. Livingston, reported a share withholding transaction related to the vesting of restricted stock units (RSUs). On September 4, 2026, 479 shares were retained to cover tax obligations, each valued at $26.61. Following this, Livingston directly holds 72,453 shares of Progyny common stock.
Progyny Inc. (NASDAQ: PGNY) is showing strong near-term sentiment that could shift to neutrality mid-term and a positive long-term bias. The stock is currently testing resistance, with specific trading strategies generated by AI models for various risk profiles, including long, breakout, and short positions based on real-time signals.
JPMorgan Chase & Co. raised its price target for Progyny (NASDAQ:PGNY) to $30.00 from $27.00, maintaining a "neutral" rating and suggesting a 17.23% upside. This follows Progyny's strong quarterly earnings, beating expectations with $0.55 EPS on $350.51 million in revenue, and the authorization of a $200 million share repurchase program. The company currently holds a "Moderate Buy" consensus rating among analysts, with an average target price of $33.91.